Induction, Consolidation, and Maintenance Therapy for Advanced Pancreatic Cancer Patients:
Clinical Trials.gov link - click here
A Randomized, Phase II study using Gem/Abraxane +/- ODSH (2-O, 3-O desulfated heparin) as first-line therapy for advanced pancreatic cancer patients:
Clinical Trials.gov link - click here
Nab-paclitaxel plus gemcitabine vs. gemcitabine alone−A Phase III multi-center global trial using gemcitabine + ABI-007 vs. gemcitabine alone in patients with advanced metastatic pancreatic cancer (Dr. Daniel Von Hoff−International PI for this study)
Clinical Trials.gov link - click here
Nab-paclitaxel +gemcitabine + Surgery for Pre-Operative Therapy for Potentially Operable pancreatic cancer Patients. (Dr. Ramesh Ramanathan−TGen Clinical Research Service, Dr. Tim Sielaff−Virginia Piper Research Institute; Dr. Jim Moser−Univ of Pittsburgh Medical Center)
Clinical Trials.gov link - click here
TH-302 (hypoxia agent) plus gemcitabine vs. gem/placebo in a Phase II front-line crossover study for patients with metastatic pancreatic cancer. (Dr. Shantan Reddy−Louisiana State Univ; Dr. Joe Stephenson−Cancer Center of the Carolinas; Dr. Peter Rosen−Disney Family Cancer Center; Dr. Gabriela Chiorian−Indiana Univ; Dr. Elise Anderes−Loyola Univ; Dr. Mitesh Borad−Mayo Clinic Arizona; Dr. Wen Wee Ma−Roswell Park Research Institute; Dr. Darren Sigal−Scripps Research Institute; Dr. Tom Dragovich−Univ of Arizona; Dr. Bilal Piperdi−Univ of Mass; Dr. Ed Garon−UCLA; Dr. Nathan Bahary−Univ of Pittsburgh Medical Center; Dr. John Seng−Virginia Piper Research Institute; Dr. Noelle LoConte−Univ of Wisconsin)
Clinical Trials.gov link - click here
A Phase II randomized, Open-Label, Multicenter Study Comparing CO-1.01 (lipid-conjugated form of gemcitabine) with gemcitabine as First-Line Therapy in patients with metastatic pancreatic cancer. (Dr. Joe Stephenson−Cancer Center of the Carolinas; Dr. Paul Ritch−Medical College of Wisconsin; Dr. John Seng−Virginia Piper Research Institute; Dr. Fay-Chi Lee−New Mexico Cancer Care Alliance)
Clinical Trials.gov link - click here
A Phase II, Open-Label, Multicenter Study using CO-1.01 as Second-line therapy for Gemcitabine-Refractory patients with Stage 4 pancreatic Adenocarcinoma and no hENT1 Expression. (Dr. Christina Gomez−Palm Beach Collaborative Research Group; Dr. Charles Henderson−Piedmont HealthCare; Dr. Paul Ritch−Medical College of Wisconsin; Dr. Tom Dragovich−Univ of Arizona; Dr. Shubham Pant−University of Oklahoma; Dr. Tom Seay−Atlanta Cancer Care; Dr. Nathan Bahary−Univ of Pittsburgh Medical Center)
Clinical Trials.gov link - click here
A randomized, Open-Label, Phase 2 trial of Gemcitabine with or without Bavituximab in Patients with Previously Untreated Stage IV Pancreatic Cancer. (Dr. Steve Anthony−Evergreen 4 Cure)
Clinical Trials.gov link - click here
A Phase 2 Placebo-controlled Double-blind trial of Dasatinib added to Gemcitabine for subjects with Locally-Advanced Pancreatic Cancer. (Dr. Tina Wood−UAB; Dr. Vincent Chung−City of Hope; Dr. Ed Greeno−Univ of Minnesota; Dr. Charles Henderson−Piedmont Healthcare; Dr. Fay-Chi Lee−New Mexico Cancer Care Alliance; Dr. Lon Smith−STOH; Dr. Colin Weekes−University of Colorado Health Sciences Center)
Clinical Trials.gov link - click here